AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04576312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
Study NCT04576312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
Study NCT06195228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib plus trametinib with or without PD-1 antibody
Description: advanced thyroid cancer patients who harbor BRAF V600E mutation
Study NCT06195228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor NTRK mutation
Study NCT06195228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
Study NCT06195228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib or anlotinib plus anti-PD-1 antibody
Description: For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
Study NCT01851512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-R (Test-Reference drug)
Study NCT01851512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-T (Reference-Test drug)
Study NCT02183974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptest
Study NCT01182961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training
Description: subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
Study NCT01182961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training 2
Description: subjects will walk on a treadmill under a progressive intensive gait protocol
Study NCT01182961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise group
Description: standard of care exercise group to improve strength and balance
Study NCT02763358 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bite Counter
Description: This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
Study NCT05711147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abutment removal
Description: 4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
Study NCT05711147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of definitive abutment
Description: Placement of the final prosthetic abutment at the moment of implantation
Study NCT05049694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zirconia crowns
Description: esthetic crowns for capping permanent molars with caries
Study NCT05049694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel crowns
Description: stainless steel crowns for capping permanent molars with caries
Study NCT03590002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic ICU Medical Transfer Tool
Description: Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
Study NCT00849329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1250mg lapatinib
Study NCT00849329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib plus esomeprazole
Description: 1250mg lapatinib plus esomeprazole 40mg
Study NCT06195228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib plus anti-PD-1 antibody
Description: Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Study NCT04404556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Journey
Description: Web-based telehealth intervention focused on adherence barriers and problem-solving
Study NCT04404556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
Study NCT01402700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visi-Pro™ Balloon Expandable Stent System
Description: Implantation of one or more study devices in the common and/or external iliac artery.
Study NCT01467804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline plus placebo of JWXYJN
Description: oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
Study NCT01467804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWXYJN plus placebo of Sertraline
Description: JWXYJN 3.6g/d plus placebo of sertraline
Study NCT06021379 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
Study NCT01718067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAKÜM system
Description: 15 minutes, twice a day.
Study NCT01718067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional manual ELTGOL technique
Description: 20 minutes twice a day
Study NCT01718067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional manual ELTGOL technique
Description: 20 minutes twice a day
Study NCT01761344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative cortisol measurement.
Description: Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
Study NCT03084484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kiwifruit addition to the diet
Description: Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
Study NCT03084484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical periodontal treatment
Description: Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
Study NCT03084484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical periodontal treatment
Description: Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
Study NCT03491917 — intervention group
Intervention type: DEVICE
Intervention: DBT plus S-View
Description: DBT plus S-View images
Study NCT03491917 — intervention group
Intervention type: DEVICE
Intervention: FFDM alone
Description: FFDM alone images
Study NCT05331924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL therapy
Description: Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
Study NCT05331924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punctal plugs
Description: Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
Study NCT05331898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: the education given increased the rational drug use of the parents.
Study NCT04777903 — intervention group
Intervention type: OTHER
Intervention: collect date about all participants
Description: a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
Study NCT02918799 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mpowerment
Description: MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
Study NCT01618877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
Study NCT01618877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
Study NCT02084342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid and sodium chloride injection
Description: 10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
Study NCT02084342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid and sodium chloride injection
Description: 10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
Study NCT02084342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 100ml, IV for 30min,before incision.
Study NCT02084342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate injection
Description: 0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
Study NCT02635425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7 eggs collection
Description: vaginal US
Study NCT02635425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full eggs collection
Description: vaginal US
Study NCT04236141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
Study NCT04236141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
Study NCT04236141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
Study NCT04236141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
Study NCT04236141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
Study NCT04236141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
Study NCT03640559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroguard
Study NCT03640559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03865316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SedLine Vs Comparator Test Group
Description: Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
Study NCT06195228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Targets: precise treatment based on the target
Description: Advanced thyroid cancer patients who had other treatment targets not included above
Study NCT05397314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Punalpin
Study NCT05397314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00401440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
Study NCT00401440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
Study NCT03668756 — intervention group
Intervention type: PROCEDURE
Intervention: Computer-Assisted Navigation TKA
Description: TKAs were performed using the image-free CAS navigation system VectorVision
Study NCT01770340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with implantation of allograft
Description: Interposition of resected neurovascular bundles with allograft Avance®
Study NCT01770340 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radical prostatectomy without implantation of allograft
Description: No interposition of resected neurvascular bundles
Study NCT00712101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab intracoronary
Description: administer abciximab bolus intracoronary during primary percutaneous coronary intervention
Study NCT00712101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abciximab intravenously
Description: administer abciximab bolus intravenously during primary percutaneous coronary intervention
Study NCT00216034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
Study NCT00216034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
Study NCT00216034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin (PSK)
Description: From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
Study NCT02509208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiClot haemostatic dressing
Description: haemostatic dressing
Study NCT00109421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ÒRÉ
Description: Community-based adolescent social network HIV/STI intervention tailored to African American culture
Study NCT03270748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GvHD prophylaxis
Description: Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
Study NCT04042480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD228A
Description: SGN-CD228A administered into the vein (IV; intravenously)
Study NCT03295305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action-Based Cognitive Remediation
Study NCT03295305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured support group
Study NCT02380131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus Capecitabine
Description: A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
Study NCT02380131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
Study NCT00157300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
Study NCT03639740 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Secukinumab 150 milligram [Cosentyx]
Description: For intervention description: see arm/group description
Study NCT05072405 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin 20 mg (Zocor®, MSD)
Description: Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
Study NCT05072405 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rosuvastatin 10 mg (Crestor®, Astra Zeneca)
Description: rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
Study NCT04259502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block
Description: The block is regional anesthesia injection techniques performed under ultrasound guidance.
Study NCT04259502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The block is regional anesthesia injection techniques performed under ultrasound guidance.
Study NCT02485717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinosad topical suspension, 0.9%
Description: Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
Study NCT02485717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
Study NCT00790517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Premier Lifestyle Intervention with DASH Diet
Description: Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
Study NCT02497703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee robot
Study NCT01941225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost 5.0 mcg
Description: Single administration
Study NCT01941225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration
Study NCT01117376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin 250 mg intravenous Q6h for 4 doses
Study NCT01117376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone
Description: Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral daily
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474
Description: ZD6474 100mg oral daily to be continued for the duration of the study.
Study NCT00613626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: ZD6474 100mg oral daily to be continued for the duration of the study.